Genetic analysis of SARS-CoV-2 reveals one vaccine could combat all infections
A genetic analysis of SARS-CoV-2 sequences reveal the virus has mutated minimally since December 2019, suggesting only one vaccine is needed to combat COVID-19.
List view / Grid view
A genetic analysis of SARS-CoV-2 sequences reveal the virus has mutated minimally since December 2019, suggesting only one vaccine is needed to combat COVID-19.
Scientists have patented their technique of inhibiting cellular growth factor signalling to stop SARS-CoV-2 replication and treat COVID-19.
Researchers report that while the spike protein and RNA polymerase proteins have stabilised, other regions of the SARS-CoV-2 genome are becoming increasingly variable.
Scientists have revealed that the cytokines IL-6 and TNF-α are two biomarkers of inflammation that can predict the severity of COVID-19.
According to a new report, artificial intelligence (AI) is vital for the rapid identification of drugs that can be repurposed to combat COVID-19.
A compound called BOLD-100, which has shown efficacy against COVID-19 in pre-clinical trials, has now outperformed remdesivir in a cytopathic effect assay.
A drug screen using machine learning has identified hundreds of potential drugs that could be used to treat COVID-19, researchers say.
The SARS-CoV-2 Spike protein from a COVID-19 vaccine candidate has been characterised by researchers, supporting the neutralising antibody response it elicits.
Five immune response biomarkers have been identified by researchers who say they can be used to classify which COVID-19 patients will survive the disease.
Researchers have sequenced SARS-CoV-2, revealing at least six strains with little variability, useful information for vaccine developers.
Research has shown T cells taken from patients with COVID-19 target the same three to eight immunodominant epitopes - most of which are not on the Spike protein.
A UK company has announced that their lung epithelium model can successfully be used to test potential treatments for COVID-19.
Researchers say computational analyses suggest the bradykinin system may explain some of the symptoms of COVID-19, providing a drug target.
After screening 12,000 existing drugs, scientists have identified 21 which prevent the replication of SARS-CoV-2 in concentrations safe for patients.
A study of the SARS-CoV-2 nonstructural protein 1 (Nsp1) showed it can supress translation and inhibit anti-viral defence mechanisms, making it a potential target for drugs.